US › Healthcare

Belite Bio Inc ADR (BLTE)

US · Healthcare · Biotechnology

$157.27+1.60%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Net profit
$-26.9M
Profit YoY
-88.7%
EPS
$-0.68
EPS estimate
$-0.64

EPS came in at -0.68 against a street estimate of -0.64 — a miss of 6.3%.

Key statistics

Market cap
$6.36B
Forward P/E
227.3
P/B
8.02
Book value
$20.23
EPS (TTM)
$-2.54
52-week high
$200.00
52-week low
$60.00
50-day MA
$147.87
200-day MA
$150.06
Beta
-1.23

Analyst view

Analysts rate Belite Bio Inc ADR a strong buy (5 buy, 0 hold, 0 sell out of 5) with an average price target of $210.50.

Shareholding

Insiders
44.27%
Institutions
23.59%

Largest institutional holders

FundStake
Darwin Global Management, Ltd.7.63%
Paradigm Biocapital Advisors LP2.78%
UBS Group AG1.92%
RTW INVESTMENTS, LLC1.78%
Millennium Management LLC1.42%
Holocene Advisors, LP1.23%
Eventide Asset Management, LLC0.89%
Deerfield Management Co0.76%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Belite Bio Inc ADR — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.